Lazard Asset Management
RGNX icon

Lazard Asset Management’s Regenxbio RGNX Stock Holding History

Lazard Asset Management’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.44M Buy
+370,375
New +$3.07M 0.01% 657
2025
Q3 		– Sell
-45,398
Closed -$372K – 2235
2025
Q2 		$372K Buy
+45,398
New +$380K ﹤0.01% 1572
2025
Q1 		– Sell
-45
Closed – – 2538
2024
Q4 		$0 Sell
45
-7,585
-99% -$71.2K ﹤0.01% 2493
2024
Q3 		$80K Buy
7,630
+7,511
+6,312% +$91.6K ﹤0.01% 1826
2024
Q2 		$0 Sell
119
-1,652
-93% -$25.7K ﹤0.01% 2394
2024
Q1 		$36K Sell
1,771
-9,736
-85% -$173K ﹤0.01% 1786
2023
Q4 		$205K Buy
11,507
+8,917
+344% +$157K ﹤0.01% 1372
2023
Q3 		$41K Buy
2,590
+107
+4% +$1.94K ﹤0.01% 1910
2023
Q2 		$48K Sell
2,483
-3,631
-59% -$70K ﹤0.01% 1846
2023
Q1 		$114K Sell
6,114
-3,110
-34% -$68.8K ﹤0.01% 1483
2022
Q4 		$208K Sell
9,224
-1,027
-10% -$23.2K ﹤0.01% 1293
2022
Q3 		$270K Buy
10,251
+505
+5% +$15K ﹤0.01% 1209
2022
Q2 		$240K Buy
9,746
+3,158
+48% +$78.9K ﹤0.01% 1233
2022
Q1 		$218K Buy
6,588
+4,548
+223% +$126K ﹤0.01% 1238
2021
Q4 		$66K Sell
2,040
-1,799
-47% -$61.3K ﹤0.01% 1620
2021
Q3 		$160K Buy
3,839
+1,293
+51% +$46.5K ﹤0.01% 1324
2021
Q2 		$98K Buy
2,546
+2,494
+4,796% +$89.2K ﹤0.01% 1347
2021
Q1 		$1K Sell
52
-1,707
-97% -$72.8K ﹤0.01% 1827
2020
Q4 		$79K Buy
1,759
+356
+25% +$12.4K ﹤0.01% 1237
2020
Q3 		$38K Sell
1,403
-569
-29% -$18.6K ﹤0.01% 1270
2020
Q2 		$72K Buy
+1,972
New +$73.5K ﹤0.01% 1109
2020
Q1 		– Sell
-1,496
Closed -$61K – 1714
2019
Q4 		$61K Buy
+1,496
New +$59.1K ﹤0.01% 1018
2018
Q3 		– Sell
-18,932
Closed -$1.36M – 1097
2018
Q2 		$1.36M Buy
+18,932
New +$904K ﹤0.01% 703

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Lazard Asset Management's RGNX Position: Q2 2026 in Review

Lazard Asset Management opened a new position in Regenxbio (RGNX) in Q2 2026: 370,375 shares worth $4.44M. The stake represents 0.01% of the portfolio and ranks #657 among its holdings. This is a return to the name: Lazard Asset Management previously reported a position in RGNX as recently as Q2 2025.

Lazard Asset Management first reported a position in RGNX in Q2 2018 and has held it in 23 quarters since. 165 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.

  • Lazard Asset Management held 370,375 shares of Regenxbio worth $4.44M as of Q2 2026.
  • Regenxbio was a new Lazard Asset Management position in Q2 2026.
  • Regenxbio made up 0.01% of Lazard Asset Management's portfolio in Q2 2026, its #657 holding.
  • Lazard Asset Management first reported a position in Regenxbio in Q2 2018 and has held it in 23 quarters since.
  • 165 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.